NO994481L - Sammensetninger og fremgangsmaater for redusering av okulaer hypertensjon - Google Patents

Sammensetninger og fremgangsmaater for redusering av okulaer hypertensjon

Info

Publication number
NO994481L
NO994481L NO994481A NO994481A NO994481L NO 994481 L NO994481 L NO 994481L NO 994481 A NO994481 A NO 994481A NO 994481 A NO994481 A NO 994481A NO 994481 L NO994481 L NO 994481L
Authority
NO
Norway
Prior art keywords
prostaglandin
compositions
methods
ocular hypertension
reducing ocular
Prior art date
Application number
NO994481A
Other languages
English (en)
Other versions
NO327713B1 (no
NO994481D0 (no
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994481(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO994481D0 publication Critical patent/NO994481D0/no
Publication of NO994481L publication Critical patent/NO994481L/no
Publication of NO327713B1 publication Critical patent/NO327713B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

En forbedret øyesammensetning, som inkluderer prostaglandinaktive midler, som er særlig anvendelig til å sette ned det intraokulære trykket i forbindelse med glaucoma. Forbedringer i IOP reduseringseffektivitet, konserveringseffektivitet og reduserte konsentrasjoner av additiver oppnås ved anvendelse av de fremlagte sammensetningene som inkluderer et prostaglandinaktivt middel (f. eks. isopropyl unoproston, en metabolitt av en F-serie prostaglandin), i forbindelse med utvalgte ikke-ioniske surfaktanter, konserveirngsmidler og ikke-ioniske tonisitetsjusterende midler.
NO19994481A 1997-03-17 1999-09-16 Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning NO327713B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en) 1997-03-17 1998-03-13 Compositions and methods for reducing ocular hypertension

Publications (3)

Publication Number Publication Date
NO994481D0 NO994481D0 (no) 1999-09-16
NO994481L true NO994481L (no) 1999-09-16
NO327713B1 NO327713B1 (no) 2009-09-14

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994481A NO327713B1 (no) 1997-03-17 1999-09-16 Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning

Country Status (32)

Country Link
EP (1) EP0969846B2 (no)
JP (2) JP4920124B2 (no)
KR (1) KR100555818B1 (no)
CN (1) CN1236775C (no)
AR (2) AR002194A1 (no)
AT (1) ATE257385T1 (no)
AU (1) AU738781B2 (no)
BR (2) BRPI9816218B1 (no)
CA (1) CA2280089C (no)
CL (1) CL2009001870A1 (no)
CO (1) CO4940427A1 (no)
CY (1) CY2526B1 (no)
CZ (1) CZ299833B6 (no)
DE (1) DE69820997T3 (no)
DK (1) DK0969846T4 (no)
EE (1) EE04091B1 (no)
ES (1) ES2214706T5 (no)
HU (1) HU228896B1 (no)
ID (1) ID22389A (no)
IL (1) IL131041A0 (no)
MY (1) MY122237A (no)
NO (1) NO327713B1 (no)
NZ (1) NZ337322A (no)
PE (1) PE61899A1 (no)
PL (1) PL197509B1 (no)
PT (1) PT969846E (no)
RU (1) RU2197970C2 (no)
SI (1) SI0969846T2 (no)
TW (1) TW527187B (no)
UA (1) UA63938C2 (no)
WO (1) WO1998041208A1 (no)
ZA (1) ZA982188B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
PT1321144E (pt) * 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
CN1933833B (zh) * 2004-03-18 2011-09-07 株式会社·R-技术上野 含有噻唑衍生物的含水组合物
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
KR20140083056A (ko) * 2006-03-17 2014-07-03 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
US20080107644A1 (en) * 2006-10-31 2008-05-08 Alcon Manufacturing, Ltd. Pai-1 binding modulators for the treatment of ocular disorders
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CA2702082A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
AU2009225931B9 (en) * 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PL2787968T3 (pl) 2011-12-07 2020-08-24 Allergan, Inc. Wydajne dostarczanie lipidów do ludzkiego filmu łzowego z użyciem wrażliwego na sól układu emulsyjnego
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
KR102487299B1 (ko) 2014-11-25 2023-01-10 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
US11752175B2 (en) * 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
CA3136356A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042936C (en) * 1990-05-22 2002-04-30 Ryuji Ueno Treatment of ocular hypertension with a synergistic combination for ophthalmic use
WO1992013836A1 (en) * 1991-02-07 1992-08-20 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
AU684950B2 (en) * 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
NO327713B1 (no) 2009-09-14
AU7035398A (en) 1998-10-12
PL197509B1 (pl) 2008-04-30
HU228896B1 (en) 2013-06-28
NO994481D0 (no) 1999-09-16
AR011192A1 (es) 2000-08-02
DK0969846T4 (da) 2010-12-20
ES2214706T5 (es) 2011-02-02
IL131041A0 (en) 2001-01-28
JP4920124B2 (ja) 2012-04-18
PT969846E (pt) 2004-05-31
DK0969846T3 (da) 2004-04-13
BRPI9816218B1 (pt) 2016-04-12
DE69820997T2 (de) 2004-12-09
EP0969846A1 (en) 2000-01-12
PE61899A1 (es) 1999-06-30
CN1236775C (zh) 2006-01-18
HUP0002194A2 (hu) 2000-12-28
JP2010043110A (ja) 2010-02-25
EP0969846B1 (en) 2004-01-07
ZA982188B (en) 1998-09-17
WO1998041208A1 (en) 1998-09-24
CZ325799A3 (cs) 2000-01-12
AU738781B2 (en) 2001-09-27
EE04091B1 (et) 2003-08-15
EE9900410A (et) 2000-04-17
CZ299833B6 (cs) 2008-12-10
ATE257385T1 (de) 2004-01-15
CA2280089C (en) 2009-03-03
CL2009001870A1 (es) 2010-01-22
CO4940427A1 (es) 2000-07-24
ES2214706T3 (es) 2004-09-16
DE69820997D1 (de) 2004-02-12
SI0969846T2 (sl) 2010-12-31
CA2280089A1 (en) 1998-09-24
MY122237A (en) 2006-04-29
SI0969846T1 (en) 2004-06-30
NZ337322A (en) 2001-05-25
JP2001515502A (ja) 2001-09-18
KR100555818B1 (ko) 2006-03-03
ID22389A (id) 1999-10-07
CN1249687A (zh) 2000-04-05
BR9808016A (pt) 2000-03-08
CY2526B1 (en) 2006-02-08
KR20000076330A (ko) 2000-12-26
EP0969846B2 (en) 2010-08-25
UA63938C2 (uk) 2004-02-16
TW527187B (en) 2003-04-11
HUP0002194A3 (en) 2012-08-28
HK1026841A1 (en) 2000-12-29
AR002194A1 (es) 1998-01-07
DE69820997T3 (de) 2011-10-06
PL335168A1 (en) 2000-04-10
RU2197970C2 (ru) 2003-02-10

Similar Documents

Publication Publication Date Title
MY122237A (en) Compositions and methods for reducing ocular hypertension
US6649602B1 (en) Use of an H1 antagonist and a safe steroid to treat eye conditions
AU2003274734A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
ES2042625T5 (es) Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
CA2294812A1 (fr) Composition pharmaceutique solide contenant des derives de benzofuranne
US6037368A (en) 8-iso- prostaglandins for glaucoma therapy
RU2004111984A (ru) Способ лечения инфекций среднего уха
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
CA2498233A1 (en) Clear ophthalmic solution comprising latanoprost as active ingredient
DK1395263T3 (da) 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk
WO1996016647A3 (en) Use of chloride channel blockers for reducing intraocular pressure
ES2183148T3 (es) Composiciones oftalmicas que contienen un inhibidor de anhidrasa carbonica y de la goma de xantano.
AP1754A (en) Pharmaceutical compositions based on azetidine derivatives.
WO2001070207A3 (en) 5ht2 agonists for controlling iop and treating glaucoma
ECSP982443A (es) Composiciones y metodos para reducir la hipertension ocular
WO1998024468A1 (en) TGFα FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
ATE289198T1 (de) Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
JP3442168B2 (ja) ケア用品
ATE227135T1 (de) Miotische wirkstoffe und hypertonische wirkstoffe enthaltende ophthalmische zusammensetzungen
ES2452026T3 (es) Prostaglandinas y análogos como agentes para disminuir la presión intraocular
MXPA04000980A (es) Tratamiento de hipertension ocular y glaucoma.
JP3151113B2 (ja) コンタクトレンズ用溶液
WO2003082257A3 (en) Method for treating ocular hypertension and glaucoma
AU2007200821A1 (en) Hypotensive lipid and timolol compositions and methods of using same

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees